Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies.
• Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
• The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover.

Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.

Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the work; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. The prevalence of the disease is also increasing.

The disease attacks the myelin sheath, the protective coating surrounding nerve fibers in the brain and spinal cord. When myelin is damaged, communication between the brain and body breaks down. The result can be numbness, vision problems, mobility impairment, cognitive difficulties and, over time, serious and lasting disability.

Available treatments can slow the progression of the disease and can even reduce relapses, but no existing options have been shown to reliably halt or reverse the underlying nerve damage. Companies are working to change that: The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is projected to reach $38.6 billion by 2030, a reflection of how large and persistent the unmet clinical need remains.

Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Rather than modulating the immune system, Lucid-MS targets protein arginine deiminase 2 (“PAD2”), an enzyme directly involved in myelin degradation. The goal is to protect and potentially restore the myelin sheath itself, addressing the underlying cause of disability rather than managing symptoms.

In preclinical animal models, Lucid-MS accelerated functional recovery, preserved myelin and reduced damage in MS mouse models. Phase 1 clinical trials in healthy human volunteers confirmed a favorable safety profile, with the drug well tolerated and no significant safety concerns reported. In March 2026, the company submitted an Investigational New Drug application to the U.S. FDA for a phase 2 trial.

In April 2026, the company announced that it had formally submitted an Investigational New Drug application to the U.S. FDA for a phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.

Supporting the phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The study uses a novel PET imaging tracer, [¹⁸F]3F4AP], developed by researchers at MGH and Harvard Medical School. The tracer is designed to directly visualize demyelinated neurons with intact axons, offering a more precise way to measure myelin damage and repair than any currently available technique. Enrollment in the pilot study recently reached its halfway point, with early imaging data showing a robust signal in acute MS lesions.

Alcohol’s impact on the brain is Quantum BioPharma’s second area of focus. Alcohol is one of the most widely consumed and heavily studied psychoactive substances on the planet, responsible for an estimated 2.6 million deaths annually. Alcohol use impairs cognition, slows reaction times, disrupts physiological function and contributes to an enormous global burden of harm. The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour. Quantum BioPharma challenged that assumption.

The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour, as the liver processes alcohol at a largely fixed rate. Quantum BioPharma challenged that assumption.

The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. In a double-blind, randomized, placebo-controlled clinical trial, unbuzzd reduced blood alcohol concentration more than 40% faster than placebo within the first 30 minutes after consumption. Participants also reported statistically significant improvements in alertness, reduced headache severity and fewer symptoms of impairment. No adverse side effects were reported.

Those results were published in the “World Journal of Pharmaceutical and Medical Research” earlier this year. The publication marked a meaningful scientific validation for a product, available online, that now sits at the intersection of consumer wellness and clinical evidence. 

Together, Lucid-MS and unbuzzd reflect a company committed to applying rigorous science where existing solutions have fallen short. Quantum BioPharma is advancing both assets with clinical data, peer-reviewed evidence and regulatory engagement, bringing genuine scientific innovation to two areas where patients have long needed better answers. 

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• The company has received a Texas DSHS Certificate of Registration for Industrial Radiation Machines, allowing research and development activities involving its registered Texatron(TM) Fusion Engine(TM) systems at Texas Tech University.
• The registration provides the principal regulatory authorization supporting the company’s planned engineering, prototype testing, and validation roadmap, under applicable Texas radiation control regulations.
• The certificate covers 12 Texatron(TM) Fusion Engine(TM) research systems, ranging from 500 kW to 1 GW, reflecting the breadth of the company’s planned development platform.
• The milestone follows months of regulatory review and supports the next phase of the company’s technical development program, including calibration, diagnostics and prototype validation.
• American Fusion(TM) Chief Technology Officer Dr. John Brandenburg is scheduled to introduce the Texatron(TM) Fusion Engine(TM) platform at a scientific conference at Fermilab on July 23, providing an opportunity for engagement with researchers and engineers.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has reached another step in its development program after receiving a Certificate of Registration for Industrial Radiation Machines from the Texas Department of State, Health Services, providing regulatory authorization to conduct testing, research and development involving its Texatron(TM) Fusion Engine(TM) systems at Texas Tech University in Lubbock, Texas.

The announcement, released on July 17, marks the completion of a regulatory review process that began several months earlier and establishes the framework under which the company can proceed with planned engineering, prototype testing and technical validation activities (https://ibn.fm/E1ZNj).

According to American Fusion(TM), the registration authorizes the company to receive, possess, acquire, transfer and use registered industrial radiation machines for research purposes in accordance with the Texas Radiation Control Act, applicable state regulations and the company’s radiation safety program.

The registration remains effective through February 28, 2034, and identifies Chief Technology Officer Dr. John E. Brandenburg as Radiation Safety Officer. The company noted that no other known material permits, licenses or regulatory approvals are required to conduct its planned testing program for the 500KW and 5 MW Texatron(TM) Fusion Engines(TM) at its approved Texas Tech research location.

American Fusion(TM) says the registration provides the regulatory structure supporting testing, research, prototype development, calibration, diagnostic evaluation and engineering validation rather than commercial deployment.

The certificate also covers a broad family of Texatron(TM) Fusion Engine(TM) research systems, authorizing work on twelve configurations ranging from 500 kilowatts to one gigawatt. Those systems include 500 kW, 1 MW, 5 MW, 10 MW, 20 MW, 30 MW, 50 MW, 75 MW, 100 MW, 250 MW, 500 MW and 1 GW research platforms.

Executive Chairman Brent Nelson described the approval as the result of years of engineering preparation, radiation safety planning and regulatory coordination, while Chief Legal Officer Michael G. Smith said the process reflected collaboration across engineering, legal, technical and regulatory teams.

Independent Director Fabrice David added that the company continues to focus on engineering innovation alongside regulatory compliance and scientific discipline as development progresses. “Today’s announcement reflects another important step in the company’s continued development. The combination of engineering innovation, regulatory discipline, and scientific rigor continues to position American Fusion for the next phase of its research and development program,” David said.

The registration supports American Fusion’s(TM) stated strategy of advancing the Texatron(TM) Fusion Engine(TM) through staged engineering work rather than attempting to accelerate directly toward commercialization. Planned activities include equipment calibration, diagnostic measurements, prototype refinement and technical validation under controlled testing conditions. 

That incremental approach also aligns with another event on the company’s calendar. On July 23, Dr. Brandenburg is scheduled to introduce the Texatron(TM) Fusion Engine(TM) platform during a scientific conference at Fermi National Accelerator Laboratory (“Fermilab”) in Batavia, Illinois (https://ibn.fm/34EI7).

According to the company, the presentation will introduce conference participants to its compact pulsed-fusion development platform, underlying confinement concepts, expanding patent portfolio and planned testing activities.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide.
• Study is evaluating technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent.
• Quantum BioPharma reports two key developments: patient enrollment in the pilot study has reached its halfway mark and preliminary imaging data is encouraging.

A key imaging study examining a novel approach to tracking multiple sclerosis (“MS”) has reached its halfway point in patient enrollment, with early results showing a meaningful signal in MS lesions. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, announced the milestone as part of its ongoing imaging collaboration with Massachusetts General Hospital, where researchers are evaluating a novel positron emission tomography (“PET”) imaging tracer that could support the development of Lucid-MS, the company’s MS drug candidate.

Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person’s life.

The disease attacks the central nervous system by damaging myelin, the protective coating around nerve fibers. This damage disrupts communication between the brain and the rest of the body. Symptoms can range from fatigue, numbness and vision problems to severe mobility impairment, cognitive difficulty and paralysis. The course of MS is unpredictable, and for many patients, the disease progresses in ways that are difficult to foresee or control.

Treatments exist that can slow the disease’s progression and reduce the frequency of relapses. But no therapy has yet demonstrated the ability to reliably halt or reverse the underlying nerve damage that drives long-term disability. That gap represents one of the central unmet needs in modern neurology. Better ways of measuring that damage, and of knowing whether a drug is actually protecting or repairing the nervous system, are urgently needed.

This is where Quantum BioPharma’s work with Massachusetts General Hospital becomes particularly significant. The study centers on a novel PET imaging technique using the tracer [¹⁸F]3F4AP, developed by Dr. Pedro Brugarolas, an investigator in radiology at MGH and assistant professor at Harvard Medical School. The technique is designed to detect demyelinated neurons that still have intact axons. That distinction matters enormously. It allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent.

The announcement highlights two key developments. First, patient enrollment in the pilot study has reached its halfway mark. Reaching that midpoint is a meaningful operational signal. It indicates the study is progressing on schedule and moving toward the dataset size needed to draw reliable conclusions.

Second, the preliminary imaging data is encouraging. The first cohort of participants has been imaged using both advanced PET/MR and total-body PET platforms. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. If those early findings hold as enrollment continues, the imaging approach could provide a more direct and quantitative way to track myelin loss and repair over time.

“We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data,” said Quantum BioPharma VP over scientific and clinical affairs Dr. Andrzej Chruscinski. “PET imaging with [¹⁸F]3F4AP has the potential to fundamentally change how we assess demyelination, providing a direct window into axonal health and enabling us to more clearly demonstrate the impact of therapies like Lucid-MS that aim to protect and restore the myelin sheath in MS.”

Brugarolas added that the ability to directly quantify demyelinated lesions with intact axons in living patients fills an important gap in MS research. “If further validated, this imaging approach could provide a more direct and quantitative measure of myelin loss and repair, which may help improve the evaluation of disease mechanisms and therapeutic response in MS,” he said.

These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. Lucid-MS previously completed phase 1 clinical trials with a favorable safety profile and was well tolerated in healthy participants, providing a strong foundation for the next stage of development. In March 2026, the company submitted an Investigational New Drug application to the FDA for a phase 2 trial.

A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• BOXABL is advancing a factory-based approach to housing that seeks to standardize production and improve cost efficiency in a traditionally fragmented industry.
• The company is targeting a large addressable market supported by a significant housing supply gap and long-term affordability challenges.
• Its modular system is designed to scale across multiple use cases, from individual homes to large residential and commercial developments.
• The company is embedding automation and AI into factory operations to improve throughput, reduce defects, and optimize production efficiency.
• BOXABL’s model pairs lower-margin home production with higher-margin service opportunities such as financing, insurance, and maintenance.

BOXABL (NASDAQ: BXBL) is a technology company focused on transforming residential construction through a factory-built, modular housing system designed for scale. By shifting homebuilding from traditional on-site processes to controlled manufacturing environments, the company aims to introduce a more standardized, efficient and repeatable approach to housing production. Its model integrates design, engineering and manufacturing into a unified system intended to improve speed, cost predictability and overall accessibility.

The company’s approach is rooted in addressing persistent structural challenges across the housing market, including affordability constraints, regulatory complexity and declining construction productivity. BOXABL’s platform is designed to streamline the building process by reducing reliance on fragmented workflows and enabling consistent output through automation and standardized components. This system-level strategy is intended to support a wide range of housing applications while improving efficiency across the value chain.

The company is headquartered in Las Vegas, Nevada.

Products

BOXABL’s product platform is built around a modular housing system designed for factory production, transportation efficiency and on-site deployment. Its core innovation is a folding building structure that allows homes to ship compactly on standard trailers and then unfold on-site into full residential units. This approach is intended to convert homebuilding into a repeatable manufacturing process with consistent quality and predictable costs.

The company’s flagship product line is the Casita, a fully finished modular home offered in multiple configurations, including studio, one-bedroom and two-bedroom layouts. Each unit includes a full kitchen, bathroom, and living space and can be delivered as a turnkey solution with financing and installation depending on the program. BOXABL also offers the Baby Box, a smaller unit built to RV code and designed for simpler setups without traditional foundation requirements, expanding accessibility and deployment flexibility.

The same modular system is designed to scale beyond individual units into larger residential and commercial applications, including single-family homes, townhomes, multifamily housing, hotels and mixed-use developments. BOXABL supports these applications through a 400,000-square-foot factory complex in Las Vegas, where it has produced more than 800 homes to date, and through a diversified go-to-market strategy that includes homeowners, builders, developers, commercial partners, and public sector deployments.

Market Opportunity

BOXABL is targeting a large and structurally undersupplied housing market, which the company estimates at approximately $2.2 trillion in total addressable demand. This figure is based on an estimated need for more than 5.4 million homes, including a 4.03 million unit shortfall combined with approximately 1.36 million annual housing starts at a median price point of around $405,000.

Within this broader market, the company focuses on the modular and manufactured housing segment, representing a serviceable addressable market of approximately $36 billion, based on roughly 103,000 manufactured homes shipped in 2024. BOXABL estimates its initial serviceable obtainable market at approximately $1 billion, based on a single-factory production capacity of 5,000 homes per year and an average turnkey price of approximately $175,000 per unit.

The company also highlights several structural drivers supporting demand, including affordability challenges affecting approximately 75% of U.S. households, a housing shortfall estimated at 4.7 million units, and regulatory burdens that can increase construction costs by roughly 42%. Additionally, construction productivity has declined significantly since 1970, reinforcing the potential need for alternative approaches that emphasize standardization and factory-based production.

Leadership Team

Paolo Tiramani, Co-Founder and Co-Chief Executive Officer, is an American entrepreneur with backgrounds in industrial design and mechanical engineering and has been associated with more than 150 patent filings, including work involving intellectual property licensing to Fortune 500 companies.

Galiano Tiramani, Co-Founder and Co-Chief Executive Officer, is a serial entrepreneur with experience in cryptocurrency arbitrage, Bitcoin ATM operations and agricultural ventures, contributing to the company’s focus on unconventional business models and emerging opportunities.

Kyle Denman, Co-Founder and Chief Product Officer, holds a Bachelor of Science in Mechanical Engineering and has contributed to numerous civil and automotive mechanical patent filings, supporting the development of BOXABL’s modular engineering platform.

Martin Costas, Chief Financial Officer, has held senior finance roles across organizations including Honeywell, Schlumberger, Nexans, Sysco and PwC, bringing experience in financial operations, reporting and corporate scale.

Shan Palaniappan, Chief Technology Officer, has more than two decades of experience in enterprise software and platform engineering, with prior leadership roles at Sagent, DataRobot and Salesforce, where he focused on cloud infrastructure and AI-enabled systems.

For more information, visit the company’s website at www.BOXABL.com/ir.

NOTE TO INVESTORS: The latest news and updates relating to BXBL are available in the company’s newsroom at https://ibn.fm/BXBL

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• The demand for key elements, including neodymium and praseodymium, and metals such as niobium, is only increasing.
• Canamera’s recent report recommends a diamond drill program of 1,500 meters across nine holes at its Schryburt Lake project.
• CEO states that “Schryburt Lake is a rare and genuinely underexplored carbonatite system in one of Canada’s most active mining districts.”

The magnets that spin electric vehicle motors and offshore wind turbines cannot be built without a small basket of rare earth elements led by neodymium and praseodymium. In addition, the high-strength steel alloys that reinforce pipelines, jet engines and defense infrastructure depend just as heavily on niobium, a metal whose supply is even more geographically concentrated than the rare earths. In that context, Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF), one of the junior exploration companies working to build supply of these essential elements, has filed an independent NI 43-101 technical report on its Schryburt Lake project in northwestern Ontario, recommending a C$1.5 million phase 1 drill program targeting rare earth and niobium mineralization across five priority target areas.

Neodymium and praseodymium, often referred to together as NdPr, are the specific rare earth elements used to make the high-performance permanent magnets found in electric vehicle motors, wind turbine generators, robotics and defense systems. In addition, the announcement of a recent supply agreement underscores just how central non-China NdPr sourcing has become to magnet manufacturers. 

That urgency is not abstract. A May 2026 analysis from the Center for Strategic and International Studies describes how, a year after Beijing tightened rare earth export controls, the United States has been racing to build alternative supply relationships with Australia, Japan and other partners, precisely because China still dominates global rare earth processing capacity.

Niobium plays a comparably outsized role, but its supply is concentrated even more tightly, in a single country. A recent analysis of niobium’s geopolitics notes that Brazil holds a near-monopoly on global production and reserves. The report also observed that there are no direct substitutes equivalent to niobium in its most critical applications, particularly microalloyed steels and high-performance superalloys used in aerospace, turbines and pipelines. One market overview puts Brazil’s share of global niobium production at roughly 90%, adding that Canada is the only other significant source, which is precisely the jurisdiction where Canamera’s Schryburt Lake project is located.

Canamera’s technical report, effective April 15, 2026, was authored by J Garry Clark, P.Geo. of Clark Exploration Consulting Inc., an independent qualified person. This report is the first comprehensive third-party technical assessment of Schryburt Lake since Canamera optioned the project. The report recommends a diamond drill program of 1,500 meters across nine holes. 

The budget outlined in the report is C$1,403,575, which includes a 15% contingency. Drilling will use helicopter-supported BQTW core rigs. One additional hole may be added depending on real-time portable X-ray fluorescence screening of core from the initial holes. The program targets five priority areas across the Schryburt Lake Carbonatite Complex. Four are established targets: Blue Jay, Goldfinch, Starling and Blackbird. The fifth, Hummingbird, is a newly added target exploration target that may be evaluated during phase 1.

These targets are grounded in real sample data, not just speculation. In 2023, a rock chip sample from the Blue Jay target returned 3.59% total rare earth oxides and 0.47% niobium pentoxide. Some individual samples graded as high as 0.66% niobium pentoxide.

A 3D magnetic inversion model, also completed in 2023, identified multiple pipe-like magnetic anomalies beneath several of the targets. These anomalies extend to depths of 600 to more than 1,000 meters, suggesting meaningful vertical exploration potential.

The project sits roughly 135 kilometers north-northeast of Pickle Lake, in Ontario’s Patricia Mining Division, an active mining region. Canamera holds the right to earn up to a 90% interest in the project under its joint venture option agreement with Bindi Metals Limited.

Canamera has applied for the Ontario Exploration Permit required to begin drilling and is continuing engagement with the Kingfisher Lake, Mishkeegogamang, Nibinamik and Wunnumin Lake First Nations as it advances toward field work. “Schryburt Lake is a rare and genuinely underexplored carbonatite system in one of Canada’s most active mining districts,” said Canamera CEO Brad Brodeur. “We believe it offers our shareholders the potential of differentiated exposure to permanent-magnet rare earths and niobium at a time of intense strategic focus on Western critical mineral supply chains.”

The Schryburt Lake report lands amid a run of exploration progress across Canamera’s broader portfolio. Just days earlier, the company expanded its auger drill program at the Turvolândia rare earth project in Brazil by 20%, after a drill hole there returned 3,255 parts per million total rare earth oxides over 13 meters from surface. The company also completed an 11-hole drill program at its Brazil-based Patos project, where field geology pointed to a distinct kamafugite-hosted rare earth target profile. 

Taking together, these updates mark significant progress for Canamera. The Schryburt Lake technical report gives the company a Canadian rare earth and niobium project with an independently reviewed development pathway. This adds to a portfolio that already includes ionic clay rare earth exploration in Brazil and critical mineral assets in the United States.

Canamera now has multiple, geologically distinct paths toward Western-sourced rare earth and niobium supply. That supply appears to offer exactly what magnet manufacturers and steelmakers are increasingly seeking.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• Earth Science Tech, a strategic holding company in the healthcare, pharmacy, and telemedicine sector, is distinct from other OTC listed companies based on its record of strong results, hard real estate assets, vertical integration, and robust corporate structure
• The company has reported year-over-year growth in revenue and gross profits since fiscal year 2024, progress attributable to careful strategic and complementary investments and acquisitions, which have not added debt to its balance sheet
• Its acquisition of Avenvi created a subsidiary that develops, manages, and finances real estate and owns property that houses ETST’s Texas pharmacy

Investopedia lists the lack of reliable information about listed companies as one of the primary risks of OTC stocks. This, according to the article, makes it difficult for investors to evaluate and ascertain the “realistic potential” of these stocks (https://ibn.fm/4qcql). However, Earth Science Tech (OTC: ETST) overcomes this long-held stigma attached to OTC stocks, emerging as an anomaly given its strong financial results (and timely filings), a robust corporate structure, vertical integration, and hard real estate assets, which, combined, set it apart from the conventional, risk-yielding attributes of “penny stocks.”

Earth Science Tech’s most recent annual report for the fiscal year ended March 31, 2026 (“FY2026”), tells the story of year-over-year growth. The company logged $35.7 million in revenue in FY2026, up from $33.1 million in FY2025 (https://ibn.fm/gmnx1) and $11.95 million in FY2024 (https://ibn.fm/cUtl7). Its gross profit grew to $25.5 million in FY 2026 from $24.3 million and $7.8 million in FY2025 and FY2024, respectively. 

According to Giorgio R. Saumat, CEO and Chairman of the Board, the fiscal 2026 results reflected the meaningful progress the company has “made over the last several years to build a business that is durable, self-sustaining, and positioned for long-term growth.” Part of this progress can be attributed to the company’s real estate asset aggregation under its Avenvi subsidiary as well as prudent cash management and capital allocation. 

Real Estate Asset Aggregation

Earth Science Tech acquired Avenvi, a dynamic real estate company, in fiscal 2025. Avenvi’s Financial Services division offers a wide range of financial products and guidance to customers to support homeownership and refinancing. Relatedly, Avenvi leverages its financial expertise to manage investment activities for ETST. 

Avenvi’s real estate development division manages and builds residential and commercial property; it owns the property housing ETST’s Mister Meds pharmacy in Texas. Avenvi currently has a portfolio of 13 properties, underscoring its strategic status as a distinct vehicle for hard-asset wealth generation. Through its operations and investments in real estate and asset management activities, Avenvi supports ETST’s healthcare operations.

Financial Prudence

In fiscal 2026, Earth Science Tech recorded several milestones that signal financial prudence, cash management, and strategic capital allocation. ETST permitted and built out its first residential property at Avenvi without adding any debt to its balance sheet. Additionally, the company acquired DOConsultation and Villas Health, redesigned and rebuilt its proprietary tech stack, relaunched MyOnlineConsultation, accelerated marketing efforts at its Peaks subsidiary, and built and operationalized the Texas location of its Mister Meds compounding pharmacy from the ground up, all without adding any debt. (The Texas property is owned and managed by Avenvi.)

This financial prudence enabled the company to enter the current financial year “in a position of real financial strength,” according to Mr. Saumat’s letter to shareholders (https://ibn.fm/kZnaN). “Looking ahead, our core focus remains on optimizing the operational frameworks of our holdings to support scalable, sustainable expansion.”

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• Greenland Mines issued more than 12 million common shares to AnorTech, valued at approximately $3.5 million at closing.
• Anorthosite is a rock type abundant in Greenland and on the moon, and AnorTech is developing proprietary processes to extract high-value materials from it.
• The transaction moves Greenland closer to the midstream segment of the critical materials value chain.

Two companies with deep roots in Greenland’s mineral landscape have formalized a relationship that could reshape how each of them is valued. Greenland Mines (NASDAQ: GRML) has closed a strategic share exchange with AnorTech Inc. (TSX-V: ANOR; OTCQB: ANORF), a deal that gives Greenland Mines its first foothold in midstream critical materials processing while giving AnorTech access to a NASDAQ-listed partner with growing capital markets presence and a portfolio of world-class Greenland assets.

The transaction, announced June 16 and formally closed by the end of the month, is structured as a share exchange rather than a cash acquisition. Greenland Mines issued 12,400,000 of its common shares to AnorTech, valued at approximately $3.5 million at closing. In return, Greenland received 19,958,503 AnorTech shares, representing an initial 9.9% equity position. 

Greenland Mines also holds an option, exercisable within six months of closing, to acquire an additional 25,168,669 AnorTech shares, which would bring its total ownership to a maximum of 19.9%. Option shares would be priced at the greater of C$0.30 or the last closing price before exercise, with consideration paid through additional Greenland Mines shares based on a 10-day volume-weighted average price.

The lock-up terms reflect the long-term orientation of the deal. AnorTech shares issued to Greenland Mines carry a 60-month contractual lock-up. Greenland Mines shares issued to AnorTech are locked up in two equal tranches, half for 12 months and half for 24 months. Neither party is treating this as a short-term trade.

To understand why this matters for Greenland Mines, it helps to understand what AnorTech is building. AnorTech owns 100% of the Gronne Bjerg anorthosite project in Greenland, located approximately 80 kilometers northeast of Nuuk on open tidewater and adjacent to significant hydroelectric potential. Anorthosite is a rock type abundant in Greenland and on the moon, and AnorTech is developing proprietary processes to extract high-value materials from it. 

Its product pipeline includes zero-waste smelter-grade alumina, high purity alumina, next-generation alumina-based catalysts for CO2 capture, CO2-free refractory cement and advanced 3D-printable cement. The company filed a U.S. provisional patent in 2025 to protect its sustainable alumina process and has shipped 15 tonnes of Gronne Bjerg anorthosite to Ontario for pilot plant testing.

High-purity alumina in particular commands significant market interest. It is a critical input for synthetic sapphire used in LED lighting, semiconductor substrates and scratch-resistant glass for smartphones and watches, applications that spread across consumer electronics, automotive and advanced manufacturing. The global HPA market is projected to reach $12.21 billion by 2030, growing at a compound annual growth rate of 22.2%.

The connection to AnorTech also brings a history that is directly relevant to Greenland Mines. AnorTech owned and operated the Sarfartoq rare earths project in Greenland for many years before Greenland Mines signed a definitive agreement to acquire the project earlier this year. AnorTech’s 24 years of accumulated knowledge on that ground now becomes a direct resource for Greenland Mines rather than a competitor asset. 

For Greenland Mines, the deal does more than add an equity position. It moves the company closer to the midstream segment of the critical materials value chain. Greenland Mines president Bo Møller Stensgaard described it as a step that “expands Greenland Mines beyond upstream resource exposure” and “aligns directly with our vision of building a North Atlantic Critical Metals Corridor linking advantaged Greenland resource assets with industrial processing opportunities in allied jurisdictions such as Iceland or North America.”

That vision is taking concrete shape. Greenland Mines already holds the Skaergaard project, one of the largest palladium-gold deposits in the world, including a new drilling program targeting a doubling of the resource to approximately 50 million contained ounces of gold, palladium, and platinum. 

The Sarfartoq rare earths project adds an estimated 27 million kilograms of neodymium oxide and 8 million kilograms of praseodymium oxide, with neodymium and praseodymium representing 25% to 40% of total rare earth oxides, among the highest ratios reported globally for a carbonatite-hosted deposit. The AnorTech relationship now layers sustainable alumina and advanced materials optionality on top of that upstream base. 

For more information, visit www.GreenlandMines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

• The company has appointed veteran medtech finance executive Sarah M. Romano as Chief Financial Officer, effective August 3, 2026.
• Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career.
• The appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally.
• The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (“SSICRS”) cardiac robotic surgery training program.
• SSICRS welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, adding public-company financial and capital markets experience as the surgical robotics developer continues its global expansion and advances regulatory initiatives. The appointment, effective August 3, comes at a time when SS Innovations is pursuing broader commercialization of its SSi Mantra robotic surgical platform while continuing preparations for U.S. Food and Drug Administration review (https://ibn.fm/91YyY).

Romano joins SS Innovations after serving as chief financial officer at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn, strengthen the company’s balance sheet and support strategic growth objectives.

Earlier executive roles included chief financial officer positions at Entero Therapeutics and Kiora Pharmaceuticals, where she managed capital raises, SEC reporting, investor relations and strategic transactions.

According to the company, Romano has raised more than $100 million through public and private financings during her career and brings experience working with emerging public companies navigating periods of operational growth and capital formation.

The appointment reflects a common step among expanding medical technology companies seeking to strengthen financial leadership as commercialization efforts become increasingly complex. The company says Romano’s experience in public-company operations and capital markets will support its ongoing expansion as it works toward broader global adoption of the SSi Mantra surgical robotic system, a platform designed to provide robotic-assisted surgical capabilities across multiple specialties while emphasizing affordability and accessibility.

“We are thrilled to welcome Sarah as our Chief Financial Officer at this critical moment in our growth journey. As we continue our global expansion, including pursuing U.S. FDA approval of our advanced, cost-effective SSi Mantra surgical robotic system, Sarah brings strong financial leadership, keen strategic vision, and extensive capital markets experience,” said Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations. “She will play an integral role in scaling and enhancing our financial operations to accommodate our anticipated growth.”

The leadership addition follows another milestone announced earlier this month that highlights a different aspect of the company’s growth strategy. On July 7, SS Innovations announced that its subsidiary, the SS International Centre for Robotics Surgery (“SSICRS”), graduated the inaugural class of its Cardiac Robotic Surgery Training program (https://ibn.fm/7twsV).

The five-day program brought together 33 healthcare professionals from seven countries for classroom instruction, live surgical demonstrations and hands-on robotic training using the SSi Mantra system. Training focused on robotic-assisted cardiac procedures, including totally endoscopic coronary artery bypass surgery, mitral valve surgery, atrial septal defect repair and related cardiac interventions.

The curriculum combined lectures, laboratory sessions, virtual instruction, scientific discussions and live case observations to familiarize participants with robotic-assisted cardiac techniques. Faculty members included internationally recognized cardiac surgeons from leading institutions in the United States, Belgium and South Korea, reflecting the company’s effort to establish an international education platform alongside its commercial operations.

SSICRS plans to expand beyond cardiac surgery by offering condensed training programs covering additional specialties, including urology, gynecology, thoracic surgery, colorectal procedures, gastrointestinal surgery and general surgery. The training center also incorporates online educational modules that complement in-person instruction through recorded lectures, assessments and continuing educational support.

SS Innovations’ strategy combines technology development with physician training infrastructure intended to support long-term clinical utilization. The company’s broader business centers on its proprietary SSi Mantra robotic surgery platform and the complementary SSi Mudra surgical instruments.

The system supports a variety of minimally invasive surgical procedures, including cardiac surgery, and has increasingly attracted attention for its work in robotic telesurgery. As of June 2026, the company reported that more than 20 cardiac telesurgeries had been successfully performed using the SSi Mantra platform. While telesurgery remains an emerging field rather than the company’s primary commercial focus, the procedures demonstrate technical capabilities that may contribute to future development opportunities.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• Forward Industries announced an expansion of its Solana treasury by over 500,000 Solana (SOL) during fiscal Q3 of 2026 at an average purchase price of around $79 per SOL.
• This brings Forward’s SOL treasury up to 7.55 million SOL as of June 30, 2026.
• During fiscal Q3, Forward sold 93,642 shares of common stock as part of its At The Market offering while delivering an annualized SOL-per-share growth of 36%.

Forward Industries (NASDAQ: FWDI), which continues to build and manage a large-scale Solana (SOL) treasury, announced that it acquired more than 500,000 SOL during fiscal Q3 of 2026, at an average purchase price of approximately $79 per SOL (https://ibn.fm/6wz2z).

This brings Forward’s SOL treasury up to 7.55 million SOL as of June 30, 2026, making it the largest SOL treasury company. Also during fiscal Q3 2026, as a part of its At The Market offering, Forward sold 93,642 shares of common stock while delivering an annualized SOL-per-share growth of 36%, which highlights Forward’s ability to raise capital from public markets in an accretive manner for shareholders.

Following its inclusion in both the Russell 2000 and Russell 3000 Indexes, Forward is positioned well to raise capital in public markets when its shares trade at a premium to net asset value (“NAV”).

This access to public capital is another tool for Forward to use alongside its industry-leading cost of capital, which it established using fwdSOL, the company’s proprietary liquid staking token, as collateral with institutional partners. This setup is beneficial as it lets Forward access liquidity, while also generating positive carry by borrowing against its SOL at a lower cost of capital than Forward’s staking yield of between 6.4% and 7.3%.

Speaking about Forward and how it performed this quarter, the Chief Investment Officer of Forward, Ryan Navi, said that “Our mandate is simple: maximize SOL per share and create long-term shareholder value. Our execution this quarter demonstrates our ability to employ multiple capital formation strategies to acquire additional SOL in a highly accretive manner.”

He also added that “By repurchasing shares when Forward trades at a discount to NAV and issuing equity when our shares trade at a premium, we dynamically allocate capital in a way that compounds SOL per share and enhances long-term intrinsic value. Our recent inclusion in the Russell 2000 and Russell 3000 further expands our access to institutional capital and broadens our investor base, creating another efficient avenue to fund SOL accumulation on terms that benefit our existing shareholders.”

About Forward Industries Inc. (NASDAQ: FWDI)

Forward Industries is building and managing one of the world’s largest Solana (SOL) treasuries, and is backed by many of the most influential investors in the digital space. Forward’s strategy is focused on creating long-term shareholder value by accumulating SOL and actively participating in the SOL ecosystem through various on-chain activities like staking, lending, and participating in decentralized finance (“DeFi”).

For more information, visit the Forward Industries website at www.ForwardIndustries.com.

NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://ibn.fm/FWDI

• The company has begun operations at its new North Texas engineering facility as it prepares to consolidate research, engineering and manufacturing activities.
• The relocation places the company closer to engineering talent, research institutions, aerospace companies and defense contractors in the Dallas-Fort Worth region.
• Expansion reflects American Fusion’s(TM) strategy of combining engineering development, intellectual property protection, and prototype testing as it advances toward commercialization.
• The company is advancing preparations for testing both its 500 kW and 5 MW Texatron(TM) Fusion Engine(TM) platforms.
• Negotiations continue with Texas Tech University regarding access to specialized testing infrastructure for the Texatron(TM) development program.
• American Fusion(TM) has filed 18 additional U.S. patent applications, expanding its intellectual property portfolio around fusion technologies.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has entered the next phase of its development program by beginning operations at a new engineering facility in North Texas while continuing preparations for expanded testing of its proprietary Texatron(TM) Fusion Engine(TM) platform.

The company announced that engineering personnel have relocated into a temporary facility in the Dallas-Fort Worth metropolitan area as construction continues on its permanent headquarters, engineering shop and research laboratory (https://ibn.fm/CGUCP). The move marks the first stage of American Fusion’s(TM) transition from Midland, Texas, positioning the company closer to one of the country’s largest engineering and aerospace corridors. 

Management believes the new location offers improved access to experienced technical talent, major transportation infrastructure, research institutions, defense contractors and industrial partners that could support future technology development.

Once construction is completed over the coming weeks, the company expects to consolidate its engineering, laboratory, fabrication, assembly and administrative operations into a single integrated facility. “This integrated environment should streamline operations, improve collaboration, accelerate engineering development, and position American Fusion for the next stage of growth,” said Brent Nelson, Executive Chairman.

The relocation represents more than a change of address. Fusion development requires close coordination among physicists, engineers, fabrication specialists and testing personnel. Bringing those teams together in one location can help streamline prototype development, accelerate design revisions and improve communication as increasingly complex engineering systems move toward testing.

American Fusion(TM) says procurement of specialized laboratory systems, instrumentation, diagnostic equipment, fabrication materials and testing hardware is nearing completion as preparations continue for the next stage of its engineering program.

Those preparations are focused on the company’s Texatron(TM) Fusion Engine(TM) platform, which remains the centerpiece of its commercialization strategy. Management plans to conduct additional testing on both its existing 500-kilowatt Texatron(TM) Fusion Engine(TM) and a larger 5-megawatt pre-production model. The company expects the testing program to generate engineering data supporting continued technology development and independent evaluation of system performance.

American Fusion(TM) also continues negotiations regarding access to specialized testing infrastructure at Texas Tech University. While definitive agreements remain under discussion, management has previously indicated that access to university facilities could provide additional testing capabilities while the company’s own engineering infrastructure continues to expand. The company currently anticipates additional testing activities during July and August, subject to completion of facility preparations, equipment installation, applicable agreements and any required approvals.

Alongside its engineering expansion, American Fusion(TM) continues placing significant emphasis on intellectual property. The company announced that it has filed 18 additional U.S. patent applications since its previous patent update on July 1.

The applications cover multiple aspects of the Texatron(TM) Fusion Engine(TM) platform, including fusion confinement architectures, hollow toroidal chamber designs, plasma confinement concepts, reactor geometries, electromagnetic field generation, fuel injection systems and related engineering technologies. 

These filings add to what has become an expanding intellectual property strategy surrounding the company’s fusion platform. American Fusion(TM) says its patent strategy is intended to support long-term commercialization by protecting multiple aspects of the Texatron(TM) platform as engineering progresses.

The company is developing fusion technologies through its wholly owned subsidiary, Kepler Fusion Technologies, following the previously completed merger that led to its corporate rebranding as American Fusion(TM). Its strategy centers on developing modular, infrastructure-grade fusion energy systems that could eventually serve industrial, commercial, defense and grid-constrained applications.

Unlike conventional large-scale fusion projects, the company’s development efforts emphasize compact reactor architectures combined with scalable engineering and disciplined intellectual property development.

While commercial fusion energy remains an emerging industry requiring significant technical milestones before widespread deployment becomes feasible, investment across the sector has accelerated in recent years as both private companies and governments continue supporting research into alternative energy technologies. Across the industry, developers are pursuing a range of approaches to plasma confinement, fuel selection and reactor architecture in an effort to demonstrate systems capable of producing commercially useful energy while overcoming longstanding engineering challenges.

Management believes bringing scientists, engineers, fabrication personnel and administrative functions together within a single integrated engineering environment will improve collaboration while supporting future prototype evaluation.

As equipment installation continues and preparations for university-supported testing advance, the coming months are expected to center on generating additional engineering data from both the 500-kilowatt and 5-megawatt Texatron(TM) Fusion Engine(TM) platforms.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN